Navigation Links
Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors
Date:7/10/2014

COMMACK, N.Y., July 2, 2014 /PRNewswire/ -- It is a great honor for Avery Biomedical Devices, Inc. (ABD) to announce the appointment of the world-renowned Thoracic and Cardiovascular surgeon, Mark E Ginsburg, M.D., to its Board of Directors.

Dr. Ginsburg, with over 34 years of experience, is currently practicing at two facilities: NY Presbyterian Hospital and Good Samaritan Regional Medical Center. Dr. Ginsburg has been implanting the Avery Breathing Pacemaker since the late 1980's and is considered an expert in the implantation of the Avery System. In addition, he has travelled the world to implant the Avery System in those patients who are unable to travel to the United States. He has published numerous scientific papers and books such as Lung Volume Reduction Surgery (LVRS) and Emphysema Treatments. In addition, he was lead investigator on several clinical trials.

Martin Dobelle, CEO, states, "We are humbled to have Dr. Ginsburg join our Board of Directors. His experience and expertise will be invaluable to the future growth of ABD."

Dr. Ginsburg states, "It is a privilege to serve on the Board of Directors of ABD. This company has served the world's need in diaphragm pacing. Exciting new products are under development in this and related arenas as well. I look forward to providing medical and surgical input to the Board."

ABOUT ABD

Avery Biomedical Devices, Inc. is a privately-held company located on Long Island, New York. It manufactures the Avery Breathing Pacemaker System: an implanted diaphragmatic pacemaker which is used to free many quadriplegics, central sleep apnea and diaphragm paralysis patients from mechanical ventilation. Most patients strongly prefer pacing to mechanical ventilation for reasons such as breathing and speech patterns, ease of eating and drinking and improved sense of smell. Since breathing pacemakers costs far less than mechanical ventilation and do not use percutaneous wire that pass through the skin (infection risk), it is the more prudent choice for life support.

The Avery Breathing Pacemaker is the only device of its kind with premarket approval from the USFDA and CE marking privileges under the European Active Implantable Medical Device Directive. Should you know of a patient with quadriplegia, central sleep apnea, diaphragm paralysis or another condition that may benefit from an Avery Breathing Pacemaker, please contact us.

CONTACT:
Martin D. Dobelle, CEO
631-864-1600
www.averybiomedical.com


'/>"/>
SOURCE Avery Biomedical Devices, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology news :

1. Nuisance seaweed found to produce compounds with biomedical potential
2. MADRID-MIT M+Vision Consortium hosts Biomedical Innovation Conference 2012
3. UMass Medical School scientist named 2012 Pew Latin-American Fellow in the Biomedical Sciences
4. 22 of Americas most promising scientists selected as Pew Biomedical Scholars
5. Top young Latin-American scientists named Pew Biomedical Fellows
6. Saladax Biomedical Enters into Master Collaboration Agreement with Bristol-Myers Squibb
7. BGI Tech and BAB jointly develop transgenic mice platform for biomedical research
8. Reproducibility Initiative to increase the value of biomedical research
9. £30 million boost for biomedical engineering research
10. MU celebrates $5 million partnership for advancing biomedical discoveries
11. CNIO participates in the ENCODE project: A stride forward in biomedical research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
(Date:6/23/2016)... NEW YORK , June, 23, 2016  The ... students to envision new ways to harness living systems ... of Modern Art (MoMA) in New York ... more than 130 participating students, showcased projects at MoMA,s ... included Paola Antonelli , MoMA,s senior curator of ...
(Date:6/23/2016)... NC (PRWEB) , ... June 23, 2016 , ... In ... University Hospital in Denmark detail how a patient who developed lymphedema after being treated ... tissue. The results could change the paradigm for dealing with this debilitating, frequent side ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the NASDAQ Composite ... Jones Industrial Average edged 0.27% lower to finish at 17,780.83; ... has initiated coverage on the following equities: Infinity Pharmaceuticals Inc. ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ), ... more about these stocks by accessing their free trade alerts ...
Breaking Biology Technology: